-
Blog BLOG
-
Product Center BRAND DYNAMICS
-
Investor INVESTOR RELATIONS
-
Contact Us CONTACT
-
Supervise SUPERVISION
R&D achievements realized! Jiankangyuan's benzoic acid argleatin tablets obtain drug registration certificate
Published Time:
2021-05-10
Recently, HealthGen (600380.SH) announced that its wholly-owned subsidiary, Shenzhen Haibin Pharmaceutical Co., Ltd., received the Drug Registration Certificate from the National Medical Products Administration for Alogliptin Benzoate Tablets (25mg).
According to the announcement, Alogliptin Benzoate Tablets (25mg specification) is an independently developed product of Shenzhen Haibin. This product is mainly used to treat type 2 diabetes. As monotherapy, it can be used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes; it can also be used in combination with metformin hydrochloride to improve glycemic control in patients with type 2 diabetes in addition to diet and exercise. As the main chemical component of anti-diabetic drugs, alogliptin benzoate is the primary drug choice for weight management in overweight patients with type 2 diabetes.
Alogliptin benzoate tablets are one of the main drug varieties in the field of diabetes treatment. According to the website of the Center for Drug Evaluation of the National Medical Products Administration and the Salda database, as of now, there are a total of 9 domestic manufacturers (including HealthGen) of this approved drug. The approval of alogliptin benzoate tablets is a recognition by the state of HealthGen's listed drugs in terms of safety, efficacy, and quality control.
HealthGen adheres to technology-driven creation of healthy living, focusing on the real needs of patients, and has built four high-barrier complex preparation platforms. Among them, the respiratory preparation R&D platform has taken the lead in breaking through the international market monopoly and has become a leading domestic inhaler preparation, strongly supporting the advancement of the national health industry. At the starting point of the new decade of "Healthy China 2030," continuing the advantages of industrial foundation, we will increase the intensity of innovation and R&D in key areas such as chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, and diagnostic reagents and equipment, continuously expanding the product lineup and categories, not only improving the efficiency of disease treatment, but also effectively providing more high-quality drug choices for chronic disease patients in China.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Sorry,当前栏目暂无内容!
您可以查看其他栏目或返回 首页
Sorry,The current column has no content!
You can view other columns or return Home